Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing high-purity, pathogen-specific bacteriophage therapeutics targeting antibiotic-resistant bacterial infections. Its lead candidates, AP-PA02 and AP-SA02, focus on chronic pulmonary infections caused by Pseudomonas aeruginosa and acute Staphylococcus aureus bacteremia, respectively. Utilizing proprietary phage discovery, engineering, and cGMP manufacturing, Armata aims to offer safer, targeted alternatives to broad-spectrum antibiotics for difficult-to-treat infections in specialized patient populations.
This description was generated via AI from an annual report. Updated about 1 year ago.